natgillin/translations-raw huggingface dataset:
However, non-clinical data with desloratadine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.
Međutim, neklinički podaci o desloratadinu ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenog potencijala, reproduktivne i razvojne toksičnosti.
• weight increased, increased appetite
• povećana tjelesna težina, povećan apetit
Desloratadine does not readily penetrate the central nervous system.
Desloratadin ne prodire lako u središnji živčani sustav.
2220 Heist-op-den-Berg Belgium
2220 Heist-op-den-Berg Belgija
Taking Aerinaze is not recommended if you are pregnant.
Ne preporučuje se uzimati Aerinaze ako ste trudni.
There were no significant differences in the efficacy of Aerinaze tablets across subgroups of patients defined by gender, age, or race.
Nije bilo značajnih razlika u djelotvornosti Aerinaze tableta između podskupina bolesnika određenih temeljem spola, dobi ili rase.
The safety and efficacy of Aerinaze in children below the age of 12 years have not been established.
Sigurnost i djelotvornost lijeka Aerinaze u djece mlađe od 12 godina nisu ustanovljene.
• anorexogenics or amphetamine-type psychostimulants
• anorektike ili psihostimulanse amfetaminske skupine
Caution should be exercised in the following patient groups:
Potreban je oprez kod primjene lijeka u sljedećim skupinama bolesnika:
Very rarely: the following other side effects reported during the marketing of desloratadine, may affect up to 1 in 10,000 people
Vrlo rijetko: sljedeće nuspojave prijavljene su nakon stavljanja desloratadina u promet i mogu se javiti u do 1 na 10 000 osoba
If you forget to take Aerinaze
Ako ste zaboravili uzeti Aerinaze
If you suddenly stop treatment, depression may occur.
Ako naglo prestanete uzimati lijek, može se javiti depresija.
The safety and efficacy of Aerinaze have not been established in this population, and there are insufficient data to give adequate dose recommendations.
Nisu ustanovljene sigurnost i djelotvornost lijeka Aerinaze u ovoj populaciji i nema dovoljno podataka da bi se mogle dati odgovarajuće preporuke za doziranje.
Treatment of the pseudoephedrine sulphate overdose is symptomatic and supportive.
Liječenje predoziranja pseudoefedrinsulfatom je simptomatsko i potporno.
The active substance and its metabolite are excreted in urine; 55-75 % of the administered dose is excreted unchanged.
Djelatna tvar i njezini metaboliti izlučuju se mokraćom, a 55-75% primijenjene doze izluči se u neizmijenjenom obliku.
• painful or difficult urination
• bolno ili otežano mokrenje
Posology The recommended dose of Aerinaze is one tablet twice a day.
Doziranje Preporučena doza lijeka Aerinaze je jedna tableta dvaput na dan.
Stop taking Aerinaze at least 48 hours before you have any skin tests since antihistamines may influence the result of the skin test.
Prestanite uzimati Aerinaze najmanje 48 sati prije kožnog testa na alergene jer antihistaminici mogu utjecati na rezultat kožnog testa.
The clinical efficacy and safety of Aerinaze tablets was evaluated in two, 2-week multicentre, randomized parallel group clinical trials involving 1,248 patients 12 to 78 years of age with seasonal allergic rhinitis, 414 of whom received Aerinaze tablets.
Klinička djelotvornost i sigurnost Aerinaze tableta ocijenjena je u dva dvotjedna multicentrična, randomizirana klinička ispitivanja s paralelnim skupinama, u koja je uključeno 1248 bolesnika sa sezonskim alergijskim rinitisom u dobi od 12 do 78 godina, od kojih je 414 uzimalo Aerinaze tablete.
If signs and symptoms such as pyrexia, erythema or many small pustules are observed, administration of Aerinaze should be discontinued and appropriate measures taken if needed.
Ako se opaze znakovi i simptomi poput pireksije, eritema ili mnogobrojnih malih pustula, primjenu lijeka Aerinaze potrebno je prekinuti i, po potrebi, poduzeti odgovarajuće mjere.
As a precautionary measure, it is preferable to avoid the use of Aerinaze during pregnancy.
Kao mjera opreza, preporučuje se izbjegavati primjenu lijeka Aerinaze tijekom trudnoće.
Desloratadine has demonstrated antiallergic properties from in vitro studies.
Desloratadin je pokazao antialergijska svojstva u ispitivanjima in vitro.
Therefore, if surgery is scheduled, it is preferable to discontinue treatment 24 hours before anaesthesia.
Stoga je, kada se planira kirurški zahvat, uputno prekinuti liječenje 24 sata prije anestezije.
Aerinaze has no or negligible influence on the ability to drive and use machines.
Aerinaze ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Speak with your doctor, pharmacist or nurse regarding whether you can drink alcohol while taking Aerinaze.
Porazgovarajte sa svojim liječnikom, ljekarnikom ili medicinskom sestrom o tome smijete li piti alkohol dok uzimate Aerinaze.
Aerinaze is also contraindicated in patients with:
Aerinaze je kontraindiciran i u bolesnika koji imaju:
What Aerinaze is
Što je Aerinaze
Hyperpyrexia, especially in children, may require treatment with tepid water sponge baths or hypothermia blanket.
Hiperpireksiju će, osobito u djece, možda trebati liječiti kupkama mlakom vodom i spužvom ili hipotermijskom dekom.
• hyperthyroidism,
• hipertireozu,
Continuous use can lead to tolerance resulting in an increased risk of overdosing.
Produljenom primjenom može se razviti tolerancija s posljedičnim povećanim rizikom od predoziranja.
• changes in the way the heart beats
• promjene u načinu otkucaja srca
Hypersensitivity to the active substances, to any of the excipients listed in section 6.1, or to adrenergic medicinal products or to loratadine.
Preosjetljivost na djelatne tvari, neku od pomoćnih tvari navedenih u dijelu 6.1 ili na adrenergičke lijekove ili na loratadin.
Continuous use may lead to taking more Aerinaze than the recommended dose to get the desired effect, resulting in an increased risk of overdosing.
Produljena primjena može dovesti do povećanog uzimanja tableta Aerinaze nego što je preporučeno kako biste postigli željeni učinak, čime se povećava rizik od predoziranja.
The apparent half-life of pseudoephedrine sulphate is 7.9 hours.
Prividni poluvijek pseudoefedrinsulfata je 7,9 sati.
Athletes should be informed that treatment with pseudoephedrine sulphate could lead to positive doping tests.
Sportaše treba upozoriti da liječenje pseudoefedrinsulfatom može dovesti do pozitivnih rezultata doping testova.
EU/1/07/399/001 2 modified-release tablets EU/1/07/399/002 4 modified-release tablets EU/1/07/399/003 7 modified-release tablets EU/1/07/399/004 10 modified-release tablets EU/1/07/399/005 14 modified-release tablets EU/1/07/399/006 20 modified-release tablets
EU/1/07/399/001 2 tablete s prilagođenim oslobađanjem EU/1/07/399/002 4 tablete s prilagođenim oslobađanjem EU/1/07/399/003 7 tableta s prilagođenim oslobađanjem EU/1/07/399/004 10 tableta s prilagođenim oslobađanjem EU/1/07/399/005 14 tableta s prilagođenim oslobađanjem EU/1/07/399/006 20 tableta s prilagođenim oslobađanjem
It has an indirect sympathomimetic effect due primarily to the release of adrenergic mediators from the post-ganglionic nerve endings.
Njegov je neizravni simpatomimetički učinak prvenstveno posljedica otpuštanja adrenergičkih medijatora iz postganglijskih živčanih završetaka.
• cardiovascular diseases such as ischaemic heart disease, tachyarrhythmia and severe hypertension,
• kardiovaskularne bolesti poput ishemijske bolesti srca, tahiaritmije i tešku hipertenziju,
As Aerinaze contains pseudoephedrine sulphate, it is also contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitor therapy or during the 2 weeks following the stopping of such treatment.
Budući da Aerinaze sadrži pseudoefedrinsulfat, također je kontraindiciran u bolesnika koji se liječe inhibitorima monoamino-oksidaze (MAO) odnosno tijekom 2 tjedna od prestanka primjene tih lijekova.
Antihistamines help to reduce allergic symptoms by preventing the effects of a substance called histamine, which is produced by the body.
Antihistaminici pomažu ublažiti simptome alergije sprječavanjem djelovanja tvari koja se zove histamin, a koja se stvara u tijelu.
Desloratadine does not inhibit CYP3A4 in vivo, and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.
Desloratadin ne inhibira CYP3A4 in vivo, a ispitivanja in vitro pokazala su da ovaj lijek ne inhibira CYP2D6 te da nije ni supstrat ni inhibitor P-glikoproteina.
Although most people do not experience drowsiness, it is recommended not to engage in activities requiring mental alertness, such as driving a car or operating machinery until you have established your own response to the medicinal product.
Iako većina ljudi neće osjetiti pospanost, preporučuje se da ne poduzimate aktivnosti koje zahtijevaju mentalnu pozornost, poput vožnje automobila ili rukovanja strojem dok ne ustanovite kako reagirate na ovaj lijek.
Talk to your doctor, pharmacist or nurse before taking Aerinaze: - if you are 60 years of age or older.
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete lijek Aerinaze: - ako imate 60 ili više godina.
Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.
Zdravstveni djelatnici mogu razmotriti prekid primjene desloratadina u bolesnika u kojih se za vrijeme liječenja pojave napadaji.
• restlessness with increased body movement
• nemir uz pojačane pokrete tijela
Patients should be informed that the treatment should be discontinued in case of hypertension, tachycardia, palpitations or cardiac arrhythmias, nausea or any other neurological sign (such as headache or increased headache).
Bolesnicima treba napomenuti da se liječenje mora prekinuti u slučaju hipertenzije, tahikardije, palpitacija ili srčanih aritmija, mučnine ili nekog drugog neurološkog simptoma (poput glavobolje ili pojačanja glavobolje).
B-2220 Heist-op-den-Berg Belgium.
B-2220 Heist-op-den-Berg Belgija
In case of alkalinisation of the urine, a partial resorption takes place.
U slučaju alkalizacije mokraće dolazi do djelomične resorpcije.
Nevertheless, as there is individual variation in response to all medicinal products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.
Ipak, s obzirom na individualne razlike u odgovoru na svaki lijek, preporučuje se savjetovati bolesnicima da ne poduzimaju aktivnosti koje zahtijevaju mentalnu pozornost, poput vožnje automobila ili rukovanja strojevima, dok ne ustanove kako reagiraju na ovaj lijek.
These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells.
Ta svojstva obuhvaćaju inhibiciju otpuštanja proupalnih citokina poput IL-4, IL-6, IL-8 i IL-13 iz ljudskih mastocita/bazofila kao i inhibiciju ekspresije adhezijske molekule P-selektina na stanicama endotela.
During reproductive toxicity studies, the combination of loratadine/pseudoephedrine sulphate was not teratogenic when administered orally to rats at doses up to 150 mg/kg/day and rabbits at doses up to 120 mg/kg/day.
U istraživanjima reproduktivne toksičnosti kombinacija loratadina i pseudoefedrinsulfata nije se pokazala teratogenom kada je peroralno primijenjena štakorima u dozama do 150 mg/kg na dan i kunićima u dozama do 120 mg/kg na dan.
• severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling)
• teške alergijske reakcije (otežano disanje, piskanje pri disanju, svrbež, koprivnjača i oticanje)
Following oral administration of Aerinaze for 14 days in normal healthy volunteers, steady-state conditions were reached on day 10 for desloratadine, 3-hydroxydesloratadine and pseudoephedrine sulphate.
Nakon peroralne primjene lijeka Aerinaze u zdravih dobrovoljaca tijekom 14 dana stanje dinamičke ravnoteže postignuto je 10. dana za desloratadin, 3-hidroksidesloratadin i pseudoefedrinsulfat.
Its elimination half-life in humans, at an approximate urinary pH of 6, ranges from 5 to 8 hours.
Poluvrijeme eliminacije u ljudi pri pH vrijednosti mokraće od približno 6 u rasponu je od 5 do 8 sati.
• decreased sense of smell
• smanjen osjet mirisa
Caution should be exercised in patients suffering from migraine who are currently being treated with ergot alkaloid vasoconstrictors (see section 4.5).
Potreban je oprez kod primjene lijeka u bolesnika koji pate od migrene i trenutno se liječe vazokonstriktorima iz skupine ergot-alkaloida (vidjeti dio 4.5).
Drinking alcohol while taking Aerinaze is not recommended.
Ne preporučuje se piti alkohol dok uzimate Aerinaze.
Apnoea is treated with respiratory assistance.
Apneja se liječi asistiranom ventilacijom.
The combination of loratadine/pseudoephedrine sulphate used in acute and multiple-dose studies, exhibited a low order of toxicity.
Kombinacija loratadina i pseudoefedrinsulfata korištena u istraživanjima akutnih i višestrukih doza pokazala je nisku toksičnost.
Desloratadine given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials.
Desloratadin primijenjen u jednoj dnevnoj dozi od 7,5 mg nije utjecao na psihomotoričke sposobnosti ispitanika u kliničkim ispitivanjima.
• pounding or irregular heart beat
• lupanje ili nepravilno kucanje srca
It is advisable to limit treatment to about 10 days, as during chronic administration the activity of pseudoephedrine sulphate may diminish.
Preporučeno je ograničiti liječenje na približno 10 dana jer se djelovanje pseudoefedrinsulfata može umanjiti tijekom kronične primjene.
Central nervous system effects
Učinci na središnji živčani sustav
Desloratadine is not removed by haemodialysis and it is not known if it is eliminated by peritoneal dialysis.
Desloratadin se ne uklanja hemodijalizom i nije poznato može li se ukloniti peritonealnom dijalizom.
In controlled clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo.
U kontroliranim kliničkim ispitivanjima pri preporučenoj dozi od 5 mg na dan incidencija somnolencije nije bila povećana u odnosu na placebo.
Oral administration of pseudoephedrine sulphate at the recommended dose can cause other sympathomimetic effects, such as increased blood pressure, tachycardia or manifestations of central nervous system excitation.
Peroralna primjena pseudoefedrinsulfata u preporučenoj dozi može izazvati i druge simpatomimetičke učinke, poput povišenja krvnog tlaka, tahikardije ili znakova ekscitacije središnjeg živčanog sustava.
Pack sizes of 2, 4, 7, 10, 14 and 20 tablets.
Veličine pakiranja od 2, 4, 7, 10, 14 i 20 tableta.
Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children, being more susceptible to develop new seizures under desloratadine treatment.
Desloratadin je potrebno primjenjivati s oprezom u bolesnika s napadajima u osobnoj ili obiteljskoj anamnezi, a osobito u male djece, koja su osjetljivija na razvoj novih napadaja tijekom liječenja desloratadinom.
No pre-clinical studies have been performed with Aerinaze.
Nisu provedena neklinička ispitivanja s lijekom Aerinaze.
The combination was not more toxic than their individual components, and observed effects were generally related to the pseudoephedrine sulphate component.
Toksičnost ove kombinacije nije bila veća od toksičnosti njezinih sastavnica, a opaženi učinci u pravilu su bili povezani s pseudoefedrinsulfatom.
Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1receptor antagonist activity.
Desloratadin je nesedativan, dugodjelujući antagonist histamina sa selektivnim antagonističkim djelovanjem na periferne H1-receptore.
Desloratadine and pseudoephedrine sulphate have been identified in breastfed newborns/infants of treated women.
Desloratadin i pseudoefedrinsulfat su nađeni u dojenoj novorođenčadi/dojenčadi liječenih žena.
Do not use this medicine after the expiry date which is stated on the outer carton and blister after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake "EXP".
• a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke.
• anamnezu hemoragijskog moždanog udara ili imaju čimbenike rizika koji bi mogli povećati rizik od hemoragijskog moždanog udara.
The rate of excretion is accelerated and the duration of action decreased in acidic urine (pH5).
Izlučivanje je brže, a trajanje djelovanja kraće u uvjetima kisele mokraće (pH 5).
In a single dose pharmacokinetic study with Aerinaze, plasma concentration of desloratadine can be detected within 30 minutes of administration.
U farmakokinetičkom ispitivanju primjene jedne doze lijeka Aerinaze koncentracija desloratadina u plazmi može se otkriti u roku od 30 minuta nakon primjene.
In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine.
U nizu farmakokinetičkih i kliničkih ispitivanja 6% ispitanika imalo je višu koncentraciju desloratadina u plazmi.
Concurrent administration with other sympathomimetics (decongestants, anorexogenics or amphetamine-type psychostimulants, antihypertensive medicinal products, tricyclic antidepressants and other antihistamines) may result in critical hypertension reactions (see section 4.4).
Istodobna primjena s drugim simpatomimeticima (dekongestivima, anorekticima ili psihostimulansima amfetaminske skupine, antihipertenzivima, tricikličkim antidepresivima i drugim antihistaminicima) može dovesti do kritičnih hipertenzivnih reakcija (vidjeti dio 4.4).
After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors because the substance is excluded from entry to the central nervous system.
Nakon peroralne primjene desloratadin selektivno blokira periferne histaminske H1-receptore jer ne prodire u središnji živčani sustav.
At the recommended dose, this medicine is not expected to affect your ability to drive or use machines.
Ne očekuje se da bi u preporučenoj dozi ovaj lijek mogao utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
Do not take more tablets than recommended on the label.
Nemojte uzeti više tableta nego što je preporučio liječnik.
As much as possible of the amount administered should be removed before the next instillation.
Prije sljedećeg ispiranja treba odstraniti što veću količinu primijenjene tekućine.
Pharmacotherapeutic group: Nasal preparations, nasal decongestants for systemic use, ATC code: R01BA52.
Farmakoterapijska skupina: Pripravci za liječenje bolesti nosa, nazalni dekongestivi za sustavnu primjenu, ATK oznaka: R01BA52.
2 modified-release tablets 4 modified-release tablets 7 modified-release tablets 10 modified-release tablets 14 modified-release tablets 20 modified-release tablets
2 tablete s prilagođenim oslobađanjem 4 tablete s prilagođenim oslobađanjem 7 tableta s prilagođenim oslobađanjem 10 tableta s prilagođenim oslobađanjem 14 tableta s prilagođenim oslobađanjem 20 tableta s prilagođenim oslobađanjem
Aerinaze is indicated in adults and adolescents 12 years and older for the symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion.
Aerinaze je indiciran u odraslih i adolescenata u dobi od 12 ili više godina za liječenje simptoma sezonskog alergijskog rinitisa kada je praćen kongestijom nosa.
Fertility There are no data available on male and female fertility.
Plodnost Nema dostupnih podataka o plodnosti u muškaraca i žena.
The safety and efficacy of Aerinaze have not been established in patients with impaired renal or hepatic function, and there are insufficient data to give adequate dose recommendations.
Nisu ustanovljene sigurnost i djelotvornost lijeka Aerinaze u bolesnika s oštećenom funkcijom bubrega ili jetre i nema dovoljno podataka da bi se mogle dati odgovarajuće preporuke za doziranje.
• Patients receiving digitalis (see section 4.5)
• u bolesnika koji uzimaju digitalis (vidjeti dio 4.5).
Reversible and irreversible MAO inhibitor(s) may cause: risk of vasoconstriction and increased blood pressure.
Reverzibilni i ireverzibilni MAO-inhibitor(i) mogu izazvati: rizik od vazokonstrikcije i povišenog krvnog tlaka.
• increased body movement
• pojačani pokreti tijela
Adverse reactions seen with Aerinaze
Nuspojave opažene uz Aerinaze
One of the active ingredients in Aerinaze, pseudoephedrine sulphate, has the potential to be abused and large doses of pseudoephedrine sulphate can be toxic.
Jedna od djelatnih tvari u lijeku Aerinaze, pseudoefedrinsulfat, se može zlorabiti, a velike doze pseudoefedrinsulfata mogu biti otrovne.
In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.
U ispitivanju učinka jedne doze u odraslih, desloratadin u dozi od 5 mg nije utjecao na standardna mjerila uspješnosti upravljanja letjelicom, uključujući pojačan subjektivni osjećaj pospanosti i zadatke vezane uz pilotiranje.
Caution should also be exercised in patients being treated with other sympathomimetics (see section 4.5).
Oprez je potreban i u bolesnika koji se liječe drugim simpatomimeticima (vidjeti dio 4.5), uključujući:
Food had no effect on the bioavailability (Cmax and AUC) of desloratadine or pseudoephedrine sulphate.
Hrana nije utjecala na bioraspoloživost (Cmax i AUC) desloratadina ni pseudoefedrinsulfata.
The blister consists of clear polychlorotrifluorethylene/polyvinyl chloride (PCTFE/PVC) film, sealed with a vinyl heat seal coated aluminium foil.
Blister se sastoji od prozirnog poliklorotrifluoroetilenskog (PCTFE)/polivinilkloridnog (PVC) filma prekrivenog aluminijskom folijom presvučenom toplinski zalijepljenim vinilom.
In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine.
U farmakokinetičkom ispitivanju višestrukih doza provedenom s tabletama desloratadina u zdravih odraslih ispitanika, pronađena su četiri ispitanika sa sporim metaboliziranjem desloratadina.
Adsorption of active substance remaining in the stomach may be attempted by administration of active charcoal suspended in water.
Može se pokušati adsorpcija preostale djelatne tvari u želucu primjenom vodene suspenzije aktivnog ugljena.
The administration of Aerinaze should be discontinued at least 48 hours before skin tests since antihistamines maybe prevent or reduce otherwise positive reaction to dermal reactivity index.
Primjenu lijeka Aerinaze treba prekinuti najmanje 48 sati prije provođenja kožnih alergijskih testova jer antihistaminici mogu spriječiti ili umanjiti stupanj pozitivne kožne reakcije.
When Aerinaze should be used
Kada se koristi Aerinaze
However, in a clinical pharmacology trial desloratadine taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol.
Međutim, u kliničkom farmakološkom ispitivanju desloratadin primijenjen istodobno s alkoholom nije pojačao štetne učinke alkohola na psihomotoričke sposobnosti.
Pharmacodynamic effects The pharmacodynamic effects of Aerinaze tablets are directly related to that of its components.
Farmakodinamički učinci lijeka Aerinaze su izravno povezani s farmakodinamikom njegovih sastavnica.
Aerinaze tablets contain a combination of two active ingredients, desloratadine which is an antihistamine and pseudoephedrine sulphate which is a decongestant.
Aerinaze tablete sadrže kombinaciju dviju djelatnih tvari - desloratadina, koji je antihistaminik i pseudoefedrinsulfata, koji je dekongestiv.
Common: the following may affect up to 1 in 10 people
Često: mogu se javiti u do 1 na 10 osoba